Comparison of Non-Operative Mesotherapy and Surgery in the Management of Superficial Lipomas

Kamal Kataria1, Meghna Venkatesh1, Sunil Chumber1, Yashwant Rathore1, Anurag Srivastava1, Anita Dhar1, Piyush Ranjan1, Rajni Yadav2, Surabhi Vyas3, Priyanka Naranje3

Submitted: 30 Apr 2020
Accepted: 12 Dec 2020
Online: 24 Feb 2021

1 Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India
2 Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
3 Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India

To cite this article: Kataria K, Venkatesh M, Chumber S, Rathore Y, Srivastava A, Dhar A, Ranjan P, Yadav R, Vyas S, Naranje P. Comparison of non-operative mesotherapy and surgery in the management of superficial lipomas. Malays J Med Sci. 2021;28(1):51–58. https://doi.org/10.21315/mjms2021.28.1.7

To link to this article: https://doi.org/10.21315/mjms2021.28.1.7

Abstract

**Background:** Lipomas are benign adipocytic tumours. Surgical excision is the gold standard for treating such lipomas, but it results in unaesthetic scarring.

**Methods:** A total of 126 patients were randomised into two groups. The patients in Group A underwent mesotherapy (n = 66) and those in Group B underwent surgery (n = 60). The patients in Group A group received six sessions of mesotherapy treatment at 2-week intervals. Both groups were followed up for 12 weeks, during which they were assessed for complications arising from treatment, reduction of the size of the lipoma and cosmetic outcomes.

**Results:** The overall mean age of the patients was 32.93 (± 10.1) years old and the mean volume of the lipomas was 2.29 (± 3.8) mL. A 55.86% (P = 0.0032) mean reduction in the volume of lipomas was noted in the patients who received mesotherapy, while one patient showed a gain of 16% by volume. The patients in Group A (cosmetic score ≥ 4: 63%) were happier with the treatment than those in Group B (cosmetic score ≥ 4: 21%).

**Conclusion:** Our findings indicate that mesotherapy modestly reduces the volume of lipomas with very few and minor complications and excellent cosmetic outcomes.

**Keywords:** deoxycholate, lipoma, mesotherapy, phosphatidylcholine

Introduction

Lipomas are adipocytic tumours which can arise in any part of the body (1). They are most often benign asymptomatic neoplasms but can cause symptoms as a result of compression or displacement of the surrounding structures. They are generally well encapsulated and homogenous but may develop calcification and haemorrhage due to trauma. Their diagnosis is mainly clinical, but an ultrasonography and fine-needle aspiration cytology (FNAC) may be required to confirm the diagnosis. The common indications for treatment of lipomas are cosmesis, progressive enlargement and fear of malignancy.

The treatment of a lipoma commonly includes simple excision beyond its capsule. This procedure usually results in scarring and may also be associated with surgical complications such as haematoma and seroma formation (2). Newer minimally invasive methods such as liposuction, laser lipolysis and endoscopic removal have better cosmetic outcomes than surgical excision. Most of these
minimally invasive methods involve making incisions of varying sizes over or away from the lipoma. Mesotherapy (injection lipolysis) has an advantage over these surgical procedures with respect to cosmesis because it does not require an incision of any sort. The term ‘mesotherapy’ was coined to describe the treatment of pathologies of tissues arising from the mesoderm. This treatment modality soon expanded to include the treatment of cellulite in obese patients when several trials reported the localised loss of adipose tissue by subcutaneous injections of phosphatidylcholine and sodium deoxycholate (3, 4). Sodium deoxycholate, the active component in mesotherapy, induces the destruction of fat cells in a non-specific fashion due to its detergent action (5, 6).

In this randomised controlled trial, our primary objective was to compare surgery and mesotherapy with respect to cosmesis and assess the reductions in the size of the lipomas in the mesotherapy group. Although a few pilot studies conducted similar trials, the data remains insufficient, and to date there have been no studies performed on the Indian population, as this study was.

Methods

This randomised controlled trial was conducted in our department from January 2017 to January 2019. Approval to conduct the study was granted by the Institute Ethics Committee. Patients aged 18 years old or older with superficial subcutaneous swellings already confirmed to be lipomas by FNAC and less than 5 cm in size (dimensions determined by ultrasonography) were included in the study. Patients with a known allergy to any ingredient in the injection or with a current infection of the overlying skin were excluded from the study. Pregnant and lactating mothers were also excluded from the study. A total of 132 patients were enrolled in the study, but only 126 were randomised into the mesotherapy and surgery groups after evaluation and consent (Figure 1). Block randomisation was used to divide the patients into two groups. All patients were assessed for pain, swelling, erythema and any additional reactions during the first 24 h. A total of six injection therapy sessions were administered at 2-week intervals to the patients in mesotherapy group (Group A). The patients’ response to treatment was assessed by ultrasonography at the end of 12 weeks in the mesotherapy group (Figure 2).

At the end of treatment, patients in both groups were compared in terms of pain during therapy, patient satisfaction, cosmesis and complications. Pain scoring was conducted using the visual analog scale (VAS). Patient satisfaction was measured on a 5-point Likert scale, where 1 denoted ‘strongly disagree’ and 5 denoted ‘strongly agree’. The success of any therapy was defined as a score of ≥ 4. Similarly, cosmetic assessment was conducted using a

![Figure 1. Consort diagram](image-url)
Mesotherapy

A 26-gauge, half-inch needle attached to a 2 mL syringe was used to inject the solution (a mixture of phosphatidylcholine and sodium deoxycholate) transcutaneously into the lipoma without any topical or local anaesthetic. In India, this solution is available as ‘+Lipolab’. Patients were treated with a volume of solution in

| Patient’s cosmetic assessment score |
|-----------------------------------|
| 1 Very unhappy | 2 Unhappy | 3 Neutral (undecided) | 4 Happy | 5 Very happy |

| Nursing officer’s cosmetic assessment score |
|---------------------------------------------|
| 1 Worse | 2 Bad | 3 Same | 4 Some improvement | 5 Excellent |

Figure 2. Measurement of response in mesotherapy group on ultrasonography. A. Pre-treatment dimensions of lipoma on ultrasonography; B. Post-treatment dimensions of lipoma on ultrasonography; C. Pretreatment appearance of lipoma on inspection; D. Post-treatment appearance of lipoma on inspection.

Figure 3. Method of cosmetic assessment.

5-point Likert scale administered by a nursing officer, both pre- and post-treatment (Figure 3). A score of ≥3 indicated that the treatment was successful. All patients in both groups were assessed for complications such as pain, swelling, rash and redness. The patients in Group B, who underwent surgery, were also observed for surgical site infections, haematoma or seroma.
Results

The study included 126 patients who met the enrolment criteria. Four patients dropped out from study during follow-up. The remaining 63 patients in the mesotherapy group and the 59 in the surgery group were analysed. Their overall mean age was 32.93 (±10.1) years old (range 18–62 years old). Ninety-six patients were aged between 20 and 40 years old. There were 24 (20%) female and 98 (80%) male patients. The two groups were comparable in terms of patients’ ages and gender and the size of lipomas (Table 1). The most common location of the lipomas overall was an upper limb (78.69%), followed by the trunk (15.58%). A total of 39 patients were found to have multiple (3 or more) lipomas: 19 of these patients were in the mesotherapy group and 20 were in the surgery group.

The length, breadth, height and volume of each lipoma, measured using sonography before any intervention (pre-treatment dimensions), were comparable in both groups (Table 1). Of millilitres equal to half of the largest dimension of the lipoma in centimetres. In cases where a lipoma measured more than 1 cm, the total area of the lesion was divided into small grids (~1.0 cm apart). A total of 0.4 cc of solution was injected into each grid using the pinch/pull technique (Figure 4). Care was taken not to inject any solution while the needle was being withdrawn, to ensure that none was deposited intradermally. Following each injection, pressure was applied directly to the site of injection for several seconds to prevent local bleeding.

Statistical Analysis

All the statistical analyses were carried out using the statistical software STATA version 14.0. Data were expressed as frequencies and percent values. Descriptive statistics such as mean, median, standard deviation (SD), range and interquartile range were calculated. Comparisons of mean or median values of the dimensions and volumes of the lipomas pre- and post-treatment were conducted using the paired t-test, as appropriate.

Figure 4.  A. Marking of the lipoma; B. Cleaning of site with spirit; C. Intralesional injection; D. Pressure to local site
the 63 patients, 55 completed six sessions of treatment. There were significant reductions in the length, breadth and height of their lipomas after mesotherapy ($P < 0.001$). Significant reductions in volume were also achieved, with an overall $P$-value of 0.0032 (Table 2). Other features such as shape and vascularity showed no changes, but the lipomas did become firm to the touch after mesotherapy.

Patients who received mesotherapy were statistically more satisfied and happier with regard to cosmesis compared to those patients who underwent surgery ($P > 0.007$) (Table 3). When the two groups were compared in terms of pain and swelling, it was observed that the patients in the mesotherapy group experienced significantly less pain (VAS score ≤ 3) than those who underwent surgery (VAS score ≥ 6). There was no need to administer analgesics to the patients in the mesotherapy group. Similarly, minimal swelling was observed at the injection sites for all patients; any swelling present resolved completely and spontaneously within 48 h. In the surgery group, however, five patients developed significant swelling at the site of the incision and were evaluated for a haematoma/seroma.

The only worrisome complication observed in the mesotherapy group was rash and redness (Figure 5), which responded to the oral antihistamine cetirizine (5 mg) and the application of a topical emollient (coconut oil or liquid paraffin); all cases resolved within 3 days. Five patients developed this complaint, and it caused two of them to drop out of the trial. Although none of the patients in the surgery group experienced complications such as rashes, five patients did develop surgical site infections and five developed a haematoma or seroma at the site of the incision. The surgical site infections were resolved after a 1-week course of oral antibiotics, but the patients who developed a haematoma or seroma had to undergo aspiration in addition to 1 course of oral antibiotics. All 10 of these cases resolved within a week and there was no recurrence.

### Table 2. Post-mesotherapy dimensions in mesotherapy group

| Variable      | Pre-treatment | Post-treatment | $P$-value | Mean percentage reduction |
|---------------|---------------|----------------|-----------|---------------------------|
| Length in cm  | 2.38 (0.86)   | 1.61 (0.78)    | 0.0000    | 32.35%                    |
| (1.1–4.8)     | (0.26–3.2)    |                |           |                           |
| Breadth in cm | 1.28 (0.88)   | 0.88 (0.78)    | 0.0000    | 31.25%                    |
| (0.27–3.5)    | (0.2–3.2)     |                |           |                           |
| Height in cm  | 1.28 (0.69)   | 0.87 (0.64)    | 0.0000    | 32.2%                     |
| (0.46–3.64)   | (0.2–2.33)    |                |           |                           |
| Volume in mL  | 2.29 (3.8)    | 0.78 (1)       | 0.0032    | 55.86%                    |
| (0.26–23.63)  | (0.10–4.5)    |                |           |                           |

### Table 3. Cosmetic assessment by patient and nursing officer

| Patient’s assessment score | Mesotherapy | Surgery |
|----------------------------|-------------|---------|
| Score 1,2                  | 9%          | 25%     |
| Score 3                    | 28%         | 54%     |
| Score 4,5                  | 63%         | 21%     |

| Nursing officer’s assessment score | Mesotherapy | Surgery |
|-----------------------------------|-------------|---------|
| Score 1,2                         | 9.26%       | 16.95%  |
| Score 3                           | 18.52%      | 54.24%  |
| Score 4,5                         | 72.22%      | 28.81%  |
advantage over other procedures with respect to cosmesis.

Michel Pistor is credited with developing mesotherapy in France in 1952, but the roots of mesotherapy can be traced back to 2000 BC in China (10). Pistor coined the term mesotherapy to describe the treatment for pathologies of tissues originating from the mesoderm. Mesotherapy initially referred to intradermal injections, but today it encompasses injections into the epidermis and dermis, as well as subcutaneous and regional injections. Mesotherapy has been advocated for treating chronic pain, arthritis, psoriasis, vascular diseases, etc. Mesotherapy with phosphatidylcholine and deoxycholate has been recently introduced for aesthetic purposes to treat cellulite (11). The downside of mesotherapy is that there are as yet no standardised protocols or formulae for the drugs administered.

In the literature, only five studies have reviewed the use of mesotherapy to manage lipomas as described in Table 4 (12–16). The negative points of all these studies were the very small sample populations used and the lack of a standardised protocol for the treatment. Neither the number of sessions nor concentration of the mesotherapy solution was kept constant. Bechara et al. (12) were the only researchers to evaluate patient satisfaction, using a VAS for this purpose. A score of 1 or 2 indicated patient satisfaction: nine patients (90%) were satisfied, while one patient (10%) was not at all happy (12). In our study we assessed patient satisfaction on a numerical scale of 1–5 and an objective nursing officer assessment score. Most patients (63%) were happy with the treatment. No

Discussion

Lipomas are the most common soft-tissue tumours encountered by surgeons. The incidence of lipomas is underreported, probably due to the asymptomatic nature of these tumours, but they are estimated to occur in 1% of the population, with an estimated prevalence rate of 2.1 per 1000 tumours. The incidence of lipomas peaks in the fifth and sixth decades of life, and they are slightly more common in men (7). The aetiology of lipomas is unknown. Several theories have identified obesity, trauma and genetics as possible contributing factors to their development. Cytogenetic studies have revealed an association between translocations and inversions of regions 12q13-15 and 6p-13q with the formation of lipomas (8).

Lipomas are benign lesions with no risk of malignant transformation, so they can be managed conservatively. Surgical excision, which at present remains the gold standard treatment, is offered when a lipoma is found to be cosmetically unappealing (9). However, surgical excision is associated with unaesthetic scarring, pain, risk of surgical site infection and, rarely, recurrence. Due to these negative effects, alternative methods of treating lipomas have recently been developed. Excision via mini incision/squeeze technique, laser lipolysis, liposuction, endoscopic resection, and injection lipolysis (mesotherapy) are the other treatment modalities available, especially for patients with multiple lipomatosis. While most of these alternative treatments also involve making incisions of varying sizes over or away from the lipoma, mesotherapy does not, thus giving it an advantage over other procedures with respect to cosmesis.

Michel Pistor is credited with developing mesotherapy in France in 1952, but the roots of mesotherapy can be traced back to 2000 BC in China (10). Pistor coined the term mesotherapy to describe the treatment for pathologies of tissues originating from the mesoderm. Mesotherapy initially referred to intradermal injections, but today it encompasses injections into the epidermis and dermis, as well as subcutaneous and regional injections. Mesotherapy has been advocated for treating chronic pain, arthritis, psoriasis, vascular diseases, etc. Mesotherapy with phosphatidylcholine and deoxycholate has been recently introduced for aesthetic purposes to treat cellulite (11). The downside of mesotherapy is that there are as yet no standardised protocols or formulae for the drugs administered.

In the literature, only five studies have reviewed the use of mesotherapy to manage lipomas as described in Table 4 (12–16). The negative points of all these studies were the very small sample populations used and the lack of a standardised protocol for the treatment. Neither the number of sessions nor concentration of the mesotherapy solution was kept constant. Bechara et al. (12) were the only researchers to evaluate patient satisfaction, using a VAS for this purpose. A score of 1 or 2 indicated patient satisfaction: nine patients (90%) were satisfied, while one patient (10%) was not at all happy (12). In our study we assessed patient satisfaction on a numerical scale of 1–5 and an objective nursing officer assessment score. Most patients (63%) were happy with the treatment. No


Table 4. Brief of studies, using mesotherapy for management of subcutaneous lipomas

| Treatment                  | Study                        | Site                        | N  | Outcome measured       | % Change in size |
|----------------------------|------------------------------|-----------------------------|----|------------------------|-----------------|
| Phosphatidylcholine/Deoxycholate | Bechara et al. (12)       | Dermal lipoma               | 30 | Cross sectional surface| 45.8% decrease  |
| Deoxycholate               | Rotunda et al. (13)         | Dermal lipoma               | 12 | Surface area           | 75% decrease    |
| Phosphatidylcholine/Deoxycholate | Koppera et al. (14)       | Dermal lipoma               | 19 | Volume                 | 44% decrease in 13/19 |
|                            |                              |                             |    |                        | 41% Increase in 6/19 |
| Steroid + beta 2 agonist   | Redman et al. (15)          | Dermal lipoma               | 10 | Volume                 | 50% decrease    |
| Triamcinolone acetonide    | Hayward et al. (16)         | Superficial and deep lipomas| 8  | Palpable dimension    | 60% reduction   |

The patient expressed the desire to undergo excision following mesotherapy. This is comparable to the patient satisfaction expressed in the studies cited above.

The main complications seen following mesotherapy were mild pain (VAS score ≤ 3), swelling at injection site during the initial 24 h–48 h and rashes over the injection site. Other studies in the literature reported similar complications, except for Hayward et al. (16), who reported hypopigmentation due to steroid injection at 4 months post-treatment. Hayward et al. (16) also reported that three patients (37.5%) developed a recurrence within 2 years; two of these patients received a second injection while the third underwent surgical excision of the lipoma. Rotunda et al. (13) observed that pain and burning sensation were more common with higher concentrations (5%) of deoxycholate.

**Conclusion**

Surgery remains the gold standard treatment for lipomas but mesotherapy is a good alternative, especially in cases of lipomatosis. Mesotherapy can be provided on an outpatient basis, does not require anaesthesia, causes significantly less pain and has excellent results with regard to cosmesis.

**Implications and Recommendations**

i) A study with a longer follow-up period is needed to monitor patients for any increases in size or recurrence of lipoma after mesotherapy

ii) The drug dosage and number of sessions of mesotherapy need to be standardised

**Acknowledgements**

None.

**Conflict of Interest**

None.

**Funds**

None.

**Authors’ Contributions**

Conception and design: KK

Analysis and interpretation of the data: AS

Critical revision of the article for important intellectual content: AD, PR

Final approval of the article: SC

Provision of study materials or patients: MV, YR

Collection and assembly of data: RY, SV, PN
Correspondence

Associate Professor Dr Kamal Kataria
MS (PGIMER, Chandigarh, India)
Department of Surgical Disciplines,
All India Institute of Medical Sciences,
New Delhi, 110001 India.
Tel: +91 11 26588663
Fax: +91 11 26588663
E-mail: drkamalkataria@gmail.com

References

1. Chandawarkar Ry, Rodriguez P, Roussalis J, Tantri MD. Minimal scar segmental extraction of lipomas: study of 122 consecutive procedures. Dermatol Surg. 2005;31:59–63. https://doi.org/10.1097/00042728-200501000-00011

2. Gingrass MK. Lipoplasty complications and their prevention. Clin Plast Surg. 1999;26:341–354. https://doi.org/10.1016/S0094-1298(20)32629-8

3. Rittes PG. The use of phosphatidylcholine for correction of localized fat deposits. Aesthetic Plast Surg. 2003;27:315–318. https://doi.org/10.1007/s00266-003-3033-y

4. Rittes PG. The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads. Dermatol Surg. 2001;27:391–392. https://doi.org/10.1046/j.1524-4725.2001.00282.x

5. Rohrich R. Mesotherapy: what is it? Does it work? Plast Reconstr Surg. 2005;115:1425. https://doi.org/10.1097/01.PRS.0000162243.34988.90

6. Rotunda AM, Suzuki H, Moy RL, Kolodney MS. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg. 2004;30:1001–1008. https://doi.org/10.1111/j.1524-4725.2004.03030.x

7. Rydholm A, Berg NO. Size, site and clinical incidence of lipoma: factors in the differential diagnosis of lipoma and sarcoma. Acta Orthop Scand. 1983;54:929–934. https://doi.org/10.3109/17453678308992936

8. Grivas TB, Psarakis SA, Kaspiris A, Liapi G. Giant lipoma of the thenar — case study and contemporary approach to its aetiopathogenicity. Hand (NY). 2009;4:173–176. https://doi.org/10.1007/s11552-008-9157-4

9. Salam GA. Lipoma excision. Am Phy. 2002;65(5):901–904.

10. Pistor M. What is mesotherapy? abstract. Chir Dent Fr. 1976;46:59.

11. Petit P. The history of mesotherapy. In: Madhere, editor. Aesthetic mesotherapy and injection lipolysis in clinical practice. Informa Healthcare; 2007. 20 p. https://doi.org/10.1201/b14484-5

12. Bechara FG, Sand M, Sand D, Rotterdam S, Stücker M, Altmeyer P, et al. Lipolysis of lipomas in patients with familial multiple lipomatosis: an ultrasonography-controlled trial. J Cutan Med Surg. 2006;10(4):155–159. https://doi.org/10.2310/7750.2006.00040

13. Rotunda AM, Ablon G, Kolodney MS. Lipomas treated with subcutaneous deoxycholate injections. J Am Acad Dermatol. 2005;53:973–978. https://doi.org/10.1016/j.jaad.2005.07.068

14. Kopera D, Binder B, Toplak H. Intralesional lipolysis with phosphatidylcholine for the treatment of lipomas: pilot study. Arch Dermatol. 2006;142:395–396. https://doi.org/10.1001/archderm.142.3.395

15. Redman LM, Moro C, Dobak J, Yu Y, Guillot TS, Greenway FL. Association of β-2 adrenergic agonist and corticosteroid injection in the treatment of lipomas. Diabetes Obes Metab. 2011;13(6):517–522. https://doi.org/10.1111/j.1463-1326.2011.01374.x

16. Hayward WA, Sibbit WL, Sibbitt RR, Muruganandan M, Rolle NA, Fangtham M, et al. Intralesional injection of triamcinolone acetonide for subcutaneous lipoma causing musculoskeletal and neurological symptoms. J Clin Aesthet Derm. 2018;11(5):38–42.